Who are Augustine Therapeutics's investors?

Augustine Therapeutics's investors include AdBio partners, Asabys Partners, Jeito Capital, Novo Holdings, PMV, V-Bio Ventures, Newton Biocapital.

Augustine Therapeutics

7 known investors

Find your way into Augustine Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Augustine Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS. Founded as a spin-off from VIB and KU Leuven, it focuses on drug development for currently untreatable complex neurological diseases.

Biotech Medical Devices

Investors · 7

AdBio partnerslisted by AdBio partnersParis

How we know: AdBio partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Asabys Partnerslisted by Asabys PartnersBarcelona

How we know: Asabys Partners's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Jeito Capitallisted by Jeito CapitalParis

Novo Holdingslisted by Novo HoldingsCopenhagen · $1.1M – $54M

How we know: Novo Holdings's portfolio page · Not right? Tell us

PMVlisted by PMVBrussels

How we know: PMV's portfolio page · Not right? Tell us

V-Bio Ventureslisted by V-Bio VenturesGhent · $270K – $2.2M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Newton BiocapitalreportedBrussels

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountSeries AMar 2025
Source ↗
Undisclosed amountSeries AJun 2024
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

WalgreensWalgreens operates a pharmacy and retail health and wellness business, offering prescription services, over-the-counter medications, health products, and photo services to consumers.

Companies working in the same space as Augustine Therapeutics.

In the news

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing roundglobenewswire.com · Mar 2025

Augustine Therapeutics raises €78 million to develop new therapies for diseases including CMT | EU-Startupseu-startups.com · Mar 2025

Frequently asked questions

What does Augustine Therapeutics do?: Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS. Founded as a spin-off from VIB and KU Leuven, it focuses on drug development for currently untreatable complex neurological diseases.
Who are Augustine Therapeutics's investors?: Augustine Therapeutics's investors include AdBio partners, Asabys Partners, Jeito Capital, Novo Holdings, PMV, V-Bio Ventures, Newton Biocapital.